TY - JOUR
T1 - Efficacy and Tolerability of the New Antiepileptic Drugs, II
T2 - Treatment of Refractory Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society
AU - French, Jacqueline A.
AU - Kanner, Andres M.
AU - Bautista, Jocelyn
AU - Abou-Khalil, Bassel
AU - Browne, Thomas
AU - Harden, Cynthia L.
AU - Theodore, William H.
AU - Bazil, Carl
AU - Stern, John
AU - Schachter, Steven C.
AU - Bergen, Donna
AU - Hirtz, Deborah
AU - Montouris, Georgia D.
AU - Nespeca, Mark
AU - Gidal, Barry
AU - Marks, William J.
AU - Turk, William R.
AU - Fischer, James H.
AU - Bourgeois, Blaise
AU - Wilner, Andrew
AU - Faught, R. Edward
AU - Sachdeo, Rajesh C.
AU - Beydoun, Ahmad
AU - Glauser, Tracy A.
PY - 2004/5
Y1 - 2004/5
N2 - Purpose: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane Library for relevant articles from 1987 to March 2003. Results: All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial seizures in adults. GBP can be effective for the treatment of mixed seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox-Gastaut syndrome. Conclusions: The choice of AED depends on seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those seizure types and syndromes for which more evidence is necessary.
AB - Purpose: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane Library for relevant articles from 1987 to March 2003. Results: All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial seizures in adults. GBP can be effective for the treatment of mixed seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox-Gastaut syndrome. Conclusions: The choice of AED depends on seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those seizure types and syndromes for which more evidence is necessary.
UR - http://www.scopus.com/inward/record.url?scp=2342514201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2342514201&partnerID=8YFLogxK
U2 - 10.1111/j.0013-9580.2004.06304.x
DO - 10.1111/j.0013-9580.2004.06304.x
M3 - Review article
C2 - 15101822
AN - SCOPUS:2342514201
VL - 45
SP - 410
EP - 423
JO - Epilepsia
JF - Epilepsia
SN - 0013-9580
IS - 5
ER -